West Pharmaceutical Services (WST) Stock Price, Fundamentals & Analysis

What WST does

West Pharmaceutical Services (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products, supplying stoppers, seals, vials, syringes, cartridges, and self-injection devices to biologic, generic, and pharmaceutical drug companies. The company also provides integrated solutions such as analytical lab services, pre-approval primary packaging support, engineering development, regulatory expertise, and after-sales technical support.

Key numbers explained

• 375.87 USD is the current share price, reflecting what investors pay for one unit of ownership in the company today.
• The trailing P/E ratio of 46.9 compares the share price to the last 12 months of earnings per share (8.02 USD), showing how much the market is willing to pay for each dollar of recent earnings.
• The forward P/E ratio of 37.7 uses expected future earnings, offering a sense of valuation based on what analysts anticipate rather than what has already been reported.
• 0.24% is the dividend yield, meaning the annual dividend represents roughly 0.24% of the current share price; the ex-dividend date is Jul 29, 2026.
• 11% of earnings are paid out as dividends, indicating the company retains most of its profit for reinvestment.
• 1.14 is the beta, a measure of volatility relative to the market; a beta above 1 suggests the stock tends to move more than the overall market.
• The 52-week price range of 223.83 – 386 shows the lowest and highest traded prices over the past year, with the current price near the upper end of that range.
• 13.8% revenue growth year over year and a 17% profit margin highlight how quickly the top line is expanding and how much of each revenue dollar remains as profit.

Recent news

Recent headlines note that Morgan Stanley upgraded West Pharmaceutical Services to Overweight and raised its price target to 400 USD from 365 USD, while also highlighting potential EPS upside to current 2027 Wall Street estimates. Other stories covered broader industry topics, including Veeva's new Falcon Router for biopharma case routing and a general look at S&P 500 stocks with potential, as well as a pick of the week at Smart Insider following a director share purchase at Ecolab.

What to watch

Investors tracking WST may want to monitor the healthcare and medical instruments sector, where peers such as Baxter International (BAX), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), Bristol Myers Squibb (BMY), AbbVie (ABBV), Solventum (SOLV), and Steris (STE) operate alongside it. As a component of the S&P 500, WST can be influenced by broad market moves, interest rate shifts, and regulatory developments affecting drug packaging and delivery systems. The next earnings report, scheduled for Oct 22, 2026, will be a key date for reviewing revenue, margins, and forward guidance.